Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy
PurposeIn this research, we established, for the first time, an immune-inflammatory prognostic score (IIPS) reflecting the balance of immune and inflammatory status to explore its prognostic value in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NI...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617681/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850038717135192064 |
|---|---|
| author | Qiang Zhao Liang Wang Xun Yang Jifeng Feng Jifeng Feng Qixun Chen Qixun Chen |
| author_facet | Qiang Zhao Liang Wang Xun Yang Jifeng Feng Jifeng Feng Qixun Chen Qixun Chen |
| author_sort | Qiang Zhao |
| collection | DOAJ |
| description | PurposeIn this research, we established, for the first time, an immune-inflammatory prognostic score (IIPS) reflecting the balance of immune and inflammatory status to explore its prognostic value in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NICT).MethodsIn this retrospective study, two hundred and five ESCC patients who received NICT were included. To ascertain whether IIPS was superior to other traditional immune-inflammatory indices (IIIs), we compared their predictive values. The association between IIPS and overall survival (OS)/disease-free survival (DFS) was also investigated. For survival analyses, the Kaplan-Meier method and Cox proportional hazard regression analyses were employed.ResultsWith a mean age of 64 years (range: 45–75 years), there were 181 (88.3%) males and 24 (11.7%) females. Sixty-four (31.2%) patients achieved pCR after NICT. A total of 79 (38.5%) patients relapsed, and 55 (26.8%) cases died. The connection between DFS/OS and IIPS suggested that their interaction was non-linear. The restricted cubic spline (RCS) model identified 200 as the ideal cutoff point for IIPS. Patients exhibiting high IIPS demonstrated significantly worse 3-year OS (63.7% vs. 82.5%, P =0.002) and DFS (47.1% vs. 75.7%, P <0.001) compared to those with low IIPS. Based on the results of the Cox regression analyses, IIPS was a predictor of OS (hazard ratio [HR] =1.864, 95% CI =1.053-3.301, P =0.033) and DFS (HR =2.225, 95% CI =1.376-3.597, P =0.001).ConclusionThe treatment efficacy of NICT for ESCC can be predicted by pretreatment IIPS. IIPS is an innovative, sensitive, and useful index that helps clinicians giving individualized treatments because of improved prognostic stratification. |
| format | Article |
| id | doaj-art-a88fef61a85e45e1a41929923eb54714 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a88fef61a85e45e1a41929923eb547142025-08-20T02:56:31ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16176811617681Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapyQiang Zhao0Liang Wang1Xun Yang2Jifeng Feng3Jifeng Feng4Qixun Chen5Qixun Chen6Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, ChinaDepartment of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, ChinaDepartment of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, ChinaDepartment of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, ChinaKey Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, ChinaDepartment of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, ChinaKey Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, ChinaPurposeIn this research, we established, for the first time, an immune-inflammatory prognostic score (IIPS) reflecting the balance of immune and inflammatory status to explore its prognostic value in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NICT).MethodsIn this retrospective study, two hundred and five ESCC patients who received NICT were included. To ascertain whether IIPS was superior to other traditional immune-inflammatory indices (IIIs), we compared their predictive values. The association between IIPS and overall survival (OS)/disease-free survival (DFS) was also investigated. For survival analyses, the Kaplan-Meier method and Cox proportional hazard regression analyses were employed.ResultsWith a mean age of 64 years (range: 45–75 years), there were 181 (88.3%) males and 24 (11.7%) females. Sixty-four (31.2%) patients achieved pCR after NICT. A total of 79 (38.5%) patients relapsed, and 55 (26.8%) cases died. The connection between DFS/OS and IIPS suggested that their interaction was non-linear. The restricted cubic spline (RCS) model identified 200 as the ideal cutoff point for IIPS. Patients exhibiting high IIPS demonstrated significantly worse 3-year OS (63.7% vs. 82.5%, P =0.002) and DFS (47.1% vs. 75.7%, P <0.001) compared to those with low IIPS. Based on the results of the Cox regression analyses, IIPS was a predictor of OS (hazard ratio [HR] =1.864, 95% CI =1.053-3.301, P =0.033) and DFS (HR =2.225, 95% CI =1.376-3.597, P =0.001).ConclusionThe treatment efficacy of NICT for ESCC can be predicted by pretreatment IIPS. IIPS is an innovative, sensitive, and useful index that helps clinicians giving individualized treatments because of improved prognostic stratification.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617681/fullesophageal squamous cell carcinomaimmune-inflammatory prognostic scoreneoadjuvant immunochemotherapyprognosissurvival |
| spellingShingle | Qiang Zhao Liang Wang Xun Yang Jifeng Feng Jifeng Feng Qixun Chen Qixun Chen Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy Frontiers in Immunology esophageal squamous cell carcinoma immune-inflammatory prognostic score neoadjuvant immunochemotherapy prognosis survival |
| title | Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy |
| title_full | Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy |
| title_fullStr | Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy |
| title_full_unstemmed | Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy |
| title_short | Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy |
| title_sort | pretreatment immune inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy |
| topic | esophageal squamous cell carcinoma immune-inflammatory prognostic score neoadjuvant immunochemotherapy prognosis survival |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617681/full |
| work_keys_str_mv | AT qiangzhao pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy AT liangwang pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy AT xunyang pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy AT jifengfeng pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy AT jifengfeng pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy AT qixunchen pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy AT qixunchen pretreatmentimmuneinflammatoryprognosticscoreinpredictingclinicaloutcomesinesophagealsquamouscellcarcinomareceivingneoadjuvantimmunochemotherapy |